Seen by the Dermatologist. Not Given the Drug.

Start with what the acne actually looks like across groups, because the prevalence numbers are close enough that they are not the story.

Perkins and colleagues, published in JEADV in 2011, compared acne across five groups of women. Prevalence: African American 37 percent, Hispanic 32, Asian 30, white 24, Continental Indian 23. A spread, but not a dramatic one.

Now post-inflammatory hyperpigmentation following that acne, from the same study. African American 65 percent. Hispanic 48. White 25. Asian 18. Continental Indian 10.

Sixty-five percent versus twenty-five. That is the actual difference, and it is not about the acne — it is about what the acne leaves behind.

Which reframes the whole appointment. For a very large number of patients, the presenting complaint is not the spot. The spot healed weeks ago. The complaint is the brown mark that is still there, that will be there in four months, that is more visible than the spot ever was and that is the reason she is in the room.

The recommendation that could not be made

A JAAD expert panel took up acne-induced macular hyperpigmentation — precisely this, the marks — and concluded that evidence-based treatment recommendations cannot be made.

That is not a panel declining to have an opinion. That is a panel assembled to produce guidance, reviewing what exists, and reporting that the evidence does not permit it.

For the most common complaint in the most common dermatologic condition, in the population where it occurs at 65 percent.

What follows from that absence is not nothing — clinicians treat this successfully every day, with retinoids, azelaic acid, tyrosinase inhibitors, sun and visible-light protection, and above all by controlling the acne so it stops generating new marks. It works. It is simply not standing on the kind of comparative evidence that would let anyone tell you which sequence, at what strength, for how long, with what expected timeline.

And the drug that ends the cycle is prescribed unevenly

Here is the finding that I find hardest to explain away.

Barbieri and colleagues, JAMA Dermatology 2020, retrospective cohort of 29,928 acne patients drawn from de-identified US electronic health records, median age 20.2, spanning 2007 to 2017.

Non-Hispanic Black patients were more likely than non-Hispanic white patients to be seen by a dermatologist — odds ratio 1.20.

They were significantly less likely to receive isotretinoin: odds ratio 0.39. Less likely to receive oral antibiotics: 0.80. Less likely to receive spironolactone: 0.68. They received more topical retinoids and topical antibiotics.

So the access-to-specialist explanation does not hold. They got into the room at a higher rate and came out with a different prescription.

Isotretinoin is the drug that stops severe acne rather than managing it. In a patient with a 65 percent likelihood of post-inflammatory hyperpigmentation, every month of continued inflammatory acne is another month of generating marks that will take a year to fade. Delaying the definitive treatment does not delay the damage; it manufactures it.

Insurance is part of it and the same paper says so: Medicaid beneficiaries were less likely to see a dermatologist at all, odds ratio 0.46, and less likely to receive systemic therapy, 0.43. But the racial difference sits on top of that, among patients who had already reached the specialist.

The program adds a second filter

Isotretinoin in the US runs through iPLEDGE, a risk management program built around pregnancy prevention, with monthly appointments, monthly laboratory work, a registration window and a pharmacy pickup window.

A matched cohort of 418 patients published in PLOS ONE in 2019 looked at what happens once people are on it. Non-white patients terminated treatment early at 43.5 percent versus 30.1 percent for white patients, p=0.010. Treatment interruptions: 12.0 percent versus 4.8 percent, p=0.017. There was no significant racial difference in how long it took to start.

Among patients who never reached the cumulative target dose of 120 mg/kg — the threshold associated with durable remission — non-white women 35.0 percent versus white women 16.7 percent; non-white men 42.2 percent versus white men 34.2 percent.

The authors attribute this primarily to the logistics of the program rather than to clinical decision-making. Monthly in-person appointments and a seven-day pickup window are a tax paid in time off work, transport and childcare, and that tax is not distributed evenly.

So the course is stopped early, the remission is not durable, the acne returns, and the marks keep coming.

What to bring into the room

Say what you are actually there for. If the marks are the problem, say the marks are the problem — not as a cosmetic aside at the end but as the reason for the visit. The treatment plan for “acne” and the treatment plan for “acne that is leaving marks I can still see in June” are not the same plan, and the second one is more urgent about controlling the inflammation.

Ask directly whether isotretinoin is appropriate, and if the answer is not yet, ask what would have to be true for it to be. A named threshold turns a vague deferral into a checkpoint.

And if you have been on topicals for eighteen months with new marks arriving faster than old ones fade — that is not a treatment that is working slowly. That is a treatment that is losing.

There is one more thing to rule out before escalating. Minocycline, a first-line oral acne antibiotic, sits near the top of two independent pharmacovigilance analyses for pigmentation signals — and whether that risk differs by race was asked nationally, in a research letter nobody can read for free.

This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.